Biocon settlement clears Pertuzumab EU launch from 2027

Biocon Limited has secured licensed launch timing for its Pertuzumab biosimilar, Pebrilzo, from early calendar 2027 in the European Union and United Kingdom and from Q3 calendar 2028 in the United States, subject to regulatory approvals. Biocon’s first disclosed Pertuzumab supply programme begins in Brazil in Q4 FY27 under a 10-year government contract.

When can Biocon launch Pebrilzo?

Biocon can launch Pebrilzo in the European Union (EU) and United Kingdom (U.K.) from early calendar 2027 and in the U.S. from Q3 calendar 2028, subject to regulatory approvals. Management said its global settlement and licence agreement with Genentech secured the earliest licensed launch dates in those markets, resolving a stated intellectual-property uncertainty before commercialisation.

The European opportunity opens in Q4 FY27, according to Chief Executive Officer and Managing Director Shreehas Tambe, with 27 markets becoming available at the outset. That timetable precedes the U.S. launch window by more than a year and creates a staged commercial sequence across Brazil, Europe and North America.

The settlement does not itself constitute regulatory approval. During Q2 FY27, Pebrilzo received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), and Biocon said it was the first monoclonal antibody biosimilar recommended under the European Medicines Agency’s tailored clinical development approach. Final approvals remain a stated condition for launches in the EU, U.K. and U.S.

What does Biocon’s Brazil Pertuzumab contract establish?

Biocon’s Brazilian contract establishes the first defined Pertuzumab supply programme, with commercial deliveries scheduled to begin in Q4 FY27. Biocon Biologics received the 10-year award under Brazil’s Productive Development Partnership (PDP) programme alongside Bahiafarma and Bionovis, giving the consortium access to the country’s public healthcare market.

The consortium received 100% allocation under the PDP programme, and the arrangement includes phased localisation of Pertuzumab. Management said the full annual run rate from the programme should begin to show in FY28, rather than in FY27, because supplies begin only in the fourth quarter of the current financial year.

Brazil is therefore the first disclosed revenue pathway in Biocon’s staged Pertuzumab plan, ahead of the early-2027 EU and U.K. launch timing and the Q3 calendar 2028 U.S. date. In Q2 FY27, Biocon also launched 13 products across Asia-Pacific, Latin America and AFMET-CIS, but it did not disclose annual Pertuzumab volumes, pricing or a revenue split for the Brazilian programme.

How does Pertuzumab fit Biocon’s biosimilars business?

Pertuzumab adds a future launch to Biocon’s biosimilars segment, which recorded Q2 FY27 revenue of Rs 2,809 crore and earnings before interest, tax, depreciation and amortisation (EBITDA) of Rs 623 crore. For H1 FY27, biosimilars revenue rose 9% year on year and the segment’s EBITDA margin was 24%.

Management said it remained comfortable with biosimilars EBITDA margins in the mid-20% range as revenue scales and operating leverage improves. That is management’s outlook rather than reported future performance, while the 24% H1 FY27 margin provides the disclosed current-period reference point.

The Pertuzumab plan follows other portfolio activity in North America and Europe. Biocon added more than Rs 100 crore in new U.S. contracts and major payer wins during Q2 FY27, with Yesintek contributing to launch-related business; management said Yesintek’s U.S. market share had reached 34%. In Europe, the company launched or expanded Ustekinumab autoinjector, Denosumab and Aflibercept and won about 20 tenders in Italy, Spain, France and Denmark.

The company is also increasing insulin capacity separately from the Pertuzumab programme. Biocon commissioned a second fill-finish line in Malaysia, and said it had received EU and U.K. approvals for that line during Q2 FY27. Those approvals relate to Insulin Glargine supply, rather than Pebrilzo, but they add capacity within the broader biosimilars network.

What could affect Pertuzumab’s reported contribution?

Regulatory decisions, contracting, supply execution and customer uptake can affect when Pertuzumab appears in reported results. The settlement sets licensed launch dates, but Biocon said U.S. contracting would take place before it serves U.S. patients and customers from Q3 calendar 2028, making market access a separate step from the legal launch date.

Biocon’s Q2 FY27 results show how logistics can shift revenue between periods. The company deferred recognition of approximately 5% of quarterly revenue on certain biosimilar shipments because of logistics issues, including those related to geopolitical conditions; the related sales were booked in October rather than September.

Chief Financial Officer Kedar Upadhye said the deferred sales were largely insulin and monoclonal antibodies, not new products. He described the shift as unusual compared with the roughly 1% sales cut-off the company typically sees, while management said the affected revenue and margins should be considered in the context of a stronger expected second half of FY27.

Management also cited high order visibility for Aflibercept, insulin Aspart, Ustekinumab and Pertuzumab, alongside inventory building and commercial preparation. The company did not provide a Pertuzumab sales forecast for the EU, U.K. or U.S., so the disclosed dates establish access timing rather than a quantified revenue contribution for those markets.

Conclusion

The Genentech settlement gives Biocon a disclosed sequence for Pebrilzo commercialisation: Brazilian supplies from Q4 FY27, an initial opening of 27 European markets in Q4 FY27, EU and U.K. launches from early calendar 2027, and a U.S. entry from Q3 calendar 2028. The positive CHMP opinion supports the European regulatory path, while the Brazilian PDP award provides the first specified multi-year supply framework.

The next milestones disclosed by management are the Q4 FY27 start of Brazilian supplies, the European market opening and the FY28 emergence of the Brazil programme’s full annual run rate. Final regulatory approvals, European contracting and tenders, U.S. launch preparations, and shipment execution after the Q2 FY27 revenue deferral remain the key matters to watch.